Studies that are currently running:

1. Evaluate the pathological, clinical and prognostic features of breast carcinoma in South Africa women 35 years or younger (in cooperation with Dept. Pathology).
    
2. The effectiveness of palliative radiotherapy of cancer of the cervix.
    
3. Randomized, Open-Label, Phase 3 Trial of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non-Small Cell Lung Cancer Of Non-Adenocarcinoma Histology
    
4. Randomised phase II study of the combination of oral vinorelbine with capecitabine versus gemcitabine in combination with paclitaxel versus gemcitabine in combination with docetaxel as first line chemotherapy in patients with metastatic breast cancer.  
    
5. An international multi-centre open-label 2-arm phase III trail of adjuvant bevacizumab in triple negative breast cancer.
    
6. A randomised phase 3 study of Pemetrexed in combination with Cisplatin versus Cisplatin monotherapy in patients with recurrent or metastatic Head and Neck Cancer.
    
7. A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastatic Hormone-resistant Prostate Cancer.
    
8. A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Transtuzumab Plus Bevacizumab.
    
9. A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive early breast cancer (EBC).
    
10. A randomized phase III, double-blind placebo-controlled multicenter trial of  Everolimus in combination with Trastuzumab and Paclitaxel, as first line therapy in women with Her2 positive locally advanced or metastatic breast cancer. Protocol No: H3E-MC-JMHR
     
11. A Randomized, Multicenter, Open-Label Phase 3 Study of Pemetrexed-Cisplatin Chemotherapy plus IMC-11F8 Versus Pemetrexed-Cisplatin Chemotherapy Alone in the first-line treatment of patients with Non-squamous stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) 
     
12. Onco 1:  A phase II study of Gemcitabine and Cisplatin in HIV positive patients with cervical cancer.